The short answer
Both are supplied lyophilised and most stable dry, cold and dark, and neither contains cysteine or methionine. The DAC form differs in one important way: its maleimide group is deliberately reactive toward thiols, which is a handling consideration the others do not have.
Key facts
- Both supplied as
- Lyophilised powder
- Cysteine / methionine
- Neither, in either compound
- Ipamorelin MW
- 711.9 Da
- CJC-1295 MW
- 3647.2 (DAC) / 3367.9 (non-DAC)
- DAC-specific concern
- Maleimide reacts with free thiols
- Avoid with DAC form
- Thiol-containing buffers
What the two share
Both lack cysteine and methionine, so disulfide chemistry and thioether oxidation do not apply to either. Both are supplied lyophilised, and both are most stable dry, cold and protected from light. Both should be reconstituted gently against the vial wall and swirled rather than shaken, since foaming indicates the air-liquid interface at which peptides denature.
The DAC form's specific reactivity
This is the one truly distinctive handling point in the category. The maleimide group exists to react with a free thiol; that is its entire purpose. It will react with any accessible thiol, not only albumin's Cys34. A buffer containing dithiothreitol, β-mercaptoethanol or free cysteine will consume the linker and destroy the conjugation chemistry before it reaches its intended target.
Research material referenced
CJC-1295 + Ipamorelin 5+5mg, third-party HPLC tested
Why that matters more than usual
For most peptides, a reducing agent in buffer is unnecessary but harmless. For the DAC form it is actively destructive, and the damage is invisible: the peptide remains intact and simply loses its ability to bind albumin. Nothing about the material would look wrong, and the half-life advantage would silently disappear.
Different masses, one common error
Ipamorelin at 711.9 Da and CJC-1295 at 3647.2 differ more than fivefold. Because the two are so routinely prepared together, using one molecular weight for the other is an easy and consequential slip. Labelling aliquots with the compound and its mass is a small discipline that prevents it.
After reconstitution
Aliquot into single-use volumes to avoid repeated freeze-thaw cycling, which concentrates solutes at the ice boundary and creates fresh interfaces each cycle. Ipamorelin's aromatic residues give it a useful 280 nm absorbance for concentration checking; CJC-1295 has aromatics too, from the tyrosines and phenylalanine in the GHRH sequence.
Frequently asked questions
Should I add a reducing agent?
No, and for the DAC form specifically it is destructive. The maleimide will react with the reducing agent's thiol instead of albumin's, silently removing the half-life advantage.
Do both compounds need the same handling?
Largely, but the DAC form's maleimide reactivity is unique to it. Neither contains cysteine or methionine.
What is the most common preparation error here?
Using one compound's molecular weight for the other. They differ more than fivefold and are usually prepared together.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubChemPubChem · CJC-1295 (CID 91971820)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Ipamorelin (CID 9831659)pubchem.ncbi.nlm.nih.gov
- PubMedStability of protein pharmaceuticals: an update. Pharm Res (PMID 20143256)pubmed.ncbi.nlm.nih.gov
- PubMedTeichman et al., Prolonged stimulation of GH & IGF-I by CJC-1295. J Clin Endocrinol Metab 2006 (PMID 16352683)pubmed.ncbi.nlm.nih.gov
- PubMedRaun et al., Ipamorelin, the first selective GH secretagogue. Eur J Endocrinol 1998 (PMID 9849822)pubmed.ncbi.nlm.nih.gov
- PubMedMüller TD et al., Ghrelin. Molecular Metabolism 2015 (PMID 26042199)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · CJC-1295 / mod GRF (1-29) (CID 56841945)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More CJC-1295 & Ipamorelin articles
- What Is CJC-1295? The Two Forms and Their MassesCJC-1295 is a GHRH analogue based on GRF(1-29) with four stabilising substitutions. Two forms exist at different masses, and they are routinely conflated.
- CJC-1295 With and Without DAC3647.2 Da against 3367.9 Da - a 279.3 Da linker separating a week-long half-life from about thirty minutes. How to tell which form you have.
- Half-Life: Why a Covalent Bond Changes EverythingMinutes for native GHRH, about thirty for Mod GRF, days for the DAC form. Each step is a specific chemical intervention against a specific clearance route.
- What Is Ipamorelin? Sequence, Receptor and SelectivityIpamorelin is a five-residue ghrelin receptor agonist, Aib-His-D-2-Nal-D-Phe-Lys-NH2, described as the first selective growth hormone secretagogue.
- How CJC-1295 Works as a GHRH AnalogueCJC-1295 agonises the GHRH receptor on pituitary somatotrophs. Why the substitutions matter and what continuous versus pulsatile stimulation implies.